New Frontiers in the Medical Therapy of Hepatocellular Carcinoma

被引:13
作者
Fulgenzi, Claudia Angela Maria [1 ,2 ]
D'Alessio, Antonio [1 ,3 ]
Talbot, Thomas [1 ]
Gennari, Alessandra [4 ]
Openshaw, Mark R. [1 ]
Demirtas, Coskun O. [5 ]
Cortellini, Alessio [1 ,6 ]
Pinato, David J. [1 ,4 ]
机构
[1] Hammersmith Hosp, Imperial Coll London, Dept Surg & Canc, London, England
[2] Univ Campus Biomed, Dept Med Oncol, Rome, Italy
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[4] Univ Piemonte Orientale, Dept Translat Med, Div Oncol, Novara, Italy
[5] Marmara Univ, Sch Med, Dept Gastroenterol, Istanbul, Turkey
[6] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy
基金
英国惠康基金;
关键词
Hepatocellular carcinoma; Immunotherapy; Systemic treatments; DOUBLE-BLIND; PHASE-III; SORAFENIB; CABOZANTINIB; BLOCKADE; TREMELIMUMAB; ATEZOLIZUMAB; COMBINATION; RESECTION; EFFICACY;
D O I
10.1159/000521837
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hepatocellular carcinoma (HCC) is the most common primary liver tumor, and it rates fourth as a cause of cancer-related death. The presence of underlying liver disease and poor chemosensitivity pose major treatment challenges in the management of HCC. However, in the last few years, the therapeutic scenario has substantially changed, and immunotherapy in the form of immune checkpoint inhibitors (ICPIs) has become an essential therapeutic strategy in this field. Summary: After controversial results of monotherapy, ICPIs have been mainly investigated in association with antiangiogenic agents or as dual checkpoint inhibition. The combination of atezolizumab plus bevacizumab has become the new therapeutic standard for unresectable HCC. Currently, a number of ICPI-based combinations are being studied in phase III clinical trials as front-line therapy for advanced HCC, with growing interest in integration of early-stage disease management in the form of adjuvant or neoadjuvant therapies. With most of the trials investigating ICPIs as first-line treatment, the second-line scenario relies mainly on tyrosine kinase inhibitors, which however have not been formally trialed after ICPIs. Key Messages: In this review, we summarize the main therapeutic advances in the systemic management of HCC focusing on the most relevant ongoing trials. We also discuss the main issues arising from a such rapidly evolving field including therapeutic sequencing and patient stratification. (c) 2022 The Author(s). Published by S. Karger AG, Basel
引用
收藏
页码:164 / 172
页数:9
相关论文
共 55 条
[1]   Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].
Abou-Alfa, G. K. ;
Meyer, T. ;
Cheng, A. -L. ;
El-Khoueiry, A. B. ;
Rimassa, L. ;
Ryoo, B. -Y. ;
Cicin, I. ;
Merle, P. ;
Chen, Y. H. ;
Park, J. -W. ;
Blanc, J. -F. ;
Bolondi, L. ;
Klumpen, H. -J. ;
Chan, S. L. ;
Zagonel, V. ;
Pressiani, T. ;
Ryu, M. -H. ;
Venook, A. P. ;
Hessel, C. ;
Borgman-Hagey, A. E. ;
Schwab, G. ;
Kelley, R. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63
[2]   TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy [J].
Akalu, Yemsratch T. ;
Rothlin, Carla V. ;
Ghosh, Sourav .
IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :165-177
[3]   Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma [J].
Akateh, Clifford ;
Black, Sylvester M. ;
Conteh, Lanla ;
Miller, Eric D. ;
Noonan, Anne ;
Elliott, Eric ;
Pawlik, Timothy M. ;
Tsung, Allan ;
Cloyd, Jordan M. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (28) :3704-3721
[4]  
Ang Celina, 2019, Oncotarget, V10, P4018, DOI 10.18632/oncotarget.26998
[5]  
[Anonymous], 2021, NEWS RELEASE
[6]   Immunotherapy after liver transplantation: Where are we now? [J].
Au, Kin Pan ;
Chok, Kenneth Siu Ho .
WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2021, 13 (10) :1267-1278
[7]   Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance [J].
Bagchi, Sreya ;
Yuan, Robert ;
Engleman, Edgar G. .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 :223-249
[8]   Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence [J].
Bergerot, Paulo ;
Lamb, Peter ;
Wang, Evelyn ;
Pal, Sumanta K. .
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12) :2185-2193
[9]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[10]   Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial [J].
Bruix, Jordi ;
Takayama, Tadatoshi ;
Mazzaferro, Vincenzo ;
Chau, Gar-Yang ;
Yang, Jiamei ;
Kudo, Masatoshi ;
Cai, Jianqiang ;
Poon, Ronnie T. ;
Han, Kwang-Hyub ;
Tak, Won Young ;
Lee, Han Chu ;
Song, Tianqiang ;
Roayaie, Sasan ;
Bolondi, Luigi ;
Lee, Kwan Sik ;
Makuuchi, Masatoshi ;
Souza, Fabricio ;
Le Berre, Marie-Aude ;
Meinhardt, Gerold ;
Llovet, Josep M. .
LANCET ONCOLOGY, 2015, 16 (13) :1344-1354